These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 3821432)

  • 1. Post-marketing surveillance in New Zealand.
    Edwards IR
    Med Toxicol; 1986; 1 Suppl 1():83-5. PubMed ID: 3821432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Privacy issues and the monitoring of sumatriptan in the New Zealand Intensive Medicines Monitoring Programme.
    Coulter DM
    Pharmacoepidemiol Drug Saf; 2001 Dec; 10(7):663-7. PubMed ID: 11980258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Intensive Vaccines Monitoring Programme (IVMP): an electronic system to monitor vaccine safety in New Zealand.
    Tatley MV; Kunac DL; McNicholas A; Zhou L; Ballantyne S; Ashton J; Stehr-Green P; Galloway Y; Reid S
    Vaccine; 2008 May; 26(22):2746-52. PubMed ID: 18430496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The New Zealand Intensive Medicines Monitoring Programme.
    Coulter DM
    Pharmacoepidemiol Drug Saf; 1998 Mar; 7(2):79-90. PubMed ID: 15073731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive monitoring of new drugs based on first prescription signals from pharmacists: a pilot study.
    van Grootheest AC; Groote JK; de Jong-van den Berg LT
    Pharmacoepidemiol Drug Saf; 2003 Sep; 12(6):475-81. PubMed ID: 14513661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of the New Zealand Intensive Medicines Monitoring Programme to study the levonorgestrel-releasing intrauterine device (Mirena).
    Zhou L; Harrison-Woolrych M; Coulter DM
    Pharmacoepidemiol Drug Saf; 2003; 12(5):371-7. PubMed ID: 12899110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sibutramine usage in New Zealand: an analysis of prescription data by the Intensive Medicines Monitoring Programme.
    Hill GR; Ashton J; Harrison-Woolrych M
    Pharmacoepidemiol Drug Saf; 2007 Nov; 16(11):1217-26. PubMed ID: 17661435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survey of neurological problems with amiodarone in the New Zealand Intensive Medicines Monitoring Programme.
    Coulter DM; Edwards IR; Savage RL
    N Z Med J; 1990 Mar; 103(885):98-100. PubMed ID: 2314744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of the New Zealand Intensive Medicines Monitoring Programme in identification of previously unrecognised signals of adverse drug reactions.
    Clark DW; Harrison-Woolrych M
    Curr Drug Saf; 2006 May; 1(2):169-78. PubMed ID: 18690928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postmarketing surveillance versus clinical trials: which benefits the patient?
    Lawson DH
    Cardiology; 1994; 85 Suppl 1():18-23. PubMed ID: 7743530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bruising associated with sibutramine: results from postmarketing surveillance in New Zealand.
    Harrison-Woolrych M; Hill GR; Clark DW
    Int J Obes (Lond); 2006 Aug; 30(8):1315-7. PubMed ID: 16491106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postmarketing surveillance.
    Oleen MA
    Can J Hosp Pharm; 1987 Oct; 40(5):171-2, 179-80. PubMed ID: 10284449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-marketing surveillance of licensed medicinal and other products.
    Griffin JP
    Health Trends; 1981 Aug; 13(3):85-8. PubMed ID: 10258571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety profile of orlistat: results of a prescription-event monitoring study.
    Acharya NV; Wilton LV; Shakir SA
    Int J Obes (Lond); 2006 Nov; 30(11):1645-52. PubMed ID: 16552401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insertion of intrauterine devices: a comparison of experience with Mirena and Multiload Cu 375 during post-marketing monitoring in New Zealand.
    Harrison-Woolrych M; Zhou L; Coulter D
    N Z Med J; 2003 Aug; 116(1179):U538. PubMed ID: 14513085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Captopril: 4 years of post marketing surveillance of all patients in New Zealand.
    Edwards IR; Coulter DM; Beasley DM; MacIntosh D
    Br J Clin Pharmacol; 1987 May; 23(5):529-36. PubMed ID: 3297125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of the Therapeutic Goods Administration and the Medicine and Medical Devices Safety Authority in evaluating complementary and alternative medicines in Australia and New Zealand.
    Ghosh D; Skinner M; Ferguson LR
    Toxicology; 2006 Apr; 221(1):88-94. PubMed ID: 16481089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The need for 'postmarketing surveillance'].
    Stricker BH; in 't Veld BA; Feenstra J
    Ned Tijdschr Geneeskd; 1999 Apr; 143(14):711-3. PubMed ID: 10347624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early detection of adverse drug events within population-based health networks: application of sequential testing methods.
    Brown JS; Kulldorff M; Chan KA; Davis RL; Graham D; Pettus PT; Andrade SE; Raebel MA; Herrinton L; Roblin D; Boudreau D; Smith D; Gurwitz JH; Gunter MJ; Platt R
    Pharmacoepidemiol Drug Saf; 2007 Dec; 16(12):1275-84. PubMed ID: 17955500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.